Background: We investigated the impact of early-(E-CMV) and late onset (L-CMV)
| INTRODUCTION
Following solid organ transplantation (SOT), immunosuppressive therapy is required to prevent graft rejection; however, immunosuppression also increases the risk of systemic infection.
1
Cytomegalovirus (CMV) is one of the most common opportunistic pathogens that may affect SOT recipients, 1,2 with an incidence of CMV infection or disease ranging between 12% and 20% and 6%
and 30%, respectively. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] The development of CMV disease depends upon factors such as (i) the organ transplanted (small bowel transplants carry the highest risk, while the risk is lowest in liver or kidney transplants); (ii) donor (D)/recipient (R) CMV status (D+/R− increases the risk of disease by up to 50%); (iii) whether preventive strategies were used (e.g., antiviral prophylaxis); (iv) the presence of acute graft rejection; and (v) viral co-infection or different CMV genotypes.
2,6,13
CMV disease, defined as evidence of infection with attributable symptoms, 14 either occurs within the first 3 months of organ trans-
plant (early-onset CMV disease [E-CMV]) or after this time point
(late onset CMV disease [L-CMV]), following the discontinuation of antiviral prophylaxis or, more infrequently, after development of resistance to antiviral treatment or breakthrough CMV disease. E-CMV and L-CMV diseases have been reported in up to 60% and 40% of SOT patients who develop CMV disease, respectively. 6 Despite prophylactic and preemptive treatment strategies, CMV disease remains an important cause of morbidity and mortality in SOT recipients; it increases the risk of graft rejection and death and decreases recipient quality of life. 2, 5, [8] [9] [10] 12, 13, [15] [16] [17] In order to improve the prognosis and clinical outcomes of transplant recipients with CMV disease, concerted efforts have been made to improve its diagnosis, prevention, and treatment. 18 CMV prevention can be attempted using antiviral prophylaxis (administration before any evidence of infection) or preemptive treatment (administration based on laboratory evidence of active but asymptomatic infection). 18 Although these approaches appear to result in similar incidences of CMV infection and disease, 18, 19 E-CMV disease usually occurs with preemptive anti-CMV therapy, 20 while in contrast L-CMV disease is often observed following prophylactic anti-CMV therapy (administered most frequently in high-risk D+/R− patients), or after the development of resistance to antiviral treatment. 1, 2, 18, [21] [22] [23] [24] Clinical trial data can provide insight into the changing patterns of CMV disease and its impact on clinical outcomes, but can also have limitations. Data from large registries or databases, however, have the potential to provide additional information in order to determine CMV disease burden among patients who underwent an SOT.
22,25
In this study, patient records from the French 'Programme de 
| METHODS

| Study design and data source
This was a retrospective matched cohort study using data from the PMSI database, which registers information for all hospitalized patients across France, including those undergoing SOT. Three related datasets from the PMSI database were used: (i) "Médecine, Chirurgie, Obstétrique et Gynécologie" (MCO) for medical, surgical, and gynecology/obstetrics short-stay hospitalizations; (ii) "Soins de Suite ou de Réadaptation" (SSR)
for follow-up and rehabilitation care; and (iii) "Fichiers Complémentaires,"
available from 2008, for drugs taken during hospital stays. Patients in these databases were identified using a unique subject identifier. The databases were accessed in accordance with French law and ethical regulations. Data on whether anti-CMV prevention therapy was used and D/R serostatus were not available in these databases.
| Study population
All patients who underwent an SOT (kidney, liver, lungs, heart, pancreas, intestine, or double organ [i.e., heart-lung, liver-intestine, and kidney-pancreas transplantation]) in French public and private hospitals between 2007 and 2011 were included.
Recipients with CMV disease were identified in an inpatient setting, based on the primary and secondary diagnoses, using the International Statistical Classification of Diseases and Related Health Problems revision 10 (ICD-10) coding (Table 1) . CMV disease was classified as E-CMV (occurring ≤3 months after SOT), L-CMV-3M (occurring beyond the third month and up to 24 months post SOT), or L-CMV-6M (occurring beyond the sixth month and up to 24 months post SOT). This classification reflects the various prophylactic regimens applied during real-world clinical practice to this patient population, which generally are 6 months'
prophylactic treatment for high-risk patients and 3 months' prophylactic treatment for low-risk patients. As the database did not specify which patients received 3 months or 6 months of prophylaxis, we conducted analyses using a broad definition of late CMV (L-CMV-3M), as well as a narrower definition (L-CMV-6M). E-CMV comprises the nonprophylactic or preemptive strategy group of patients.
| Index date
The index date for recipients with CMV disease was defined as the date of the first hospital admission with a diagnosis of CMV disease.
This approach was required because the precise date of diagnosis of CMV disease during hospitalization was not available. The index date for controls (i.e., patients without CMV disease) was the date of initial admission for transplantation plus the time from the date of transplantation to CMV disease diagnosis of the matched recipient.
| Matching techniques
Each recipient diagnosed with CMV disease was matched to two controls according to age, gender, target organ, and previous/ simultaneous occurrence of graft rejection, identified based on ICD- with CMV disease were excluded from the analysis.
| Study outcomes
Transplant recipients were followed for up to 24 months after the index date. Outcomes assessed were as follows: (i) graft rejection, defined based on primary and secondary diagnoses, using ICD-10 codes ( 
| Statistical analyses
Baseline characteristics and study outcomes were subject to descriptive statistics. Categorical variables were compared using the chi-square test or Fisher's exact test and continuous variables using Student's t test or Wilcoxon test. The time from the index date to graft rejection, graft failure, or all-cause mortality was described using Kaplan-Meier survival curves for recipients with CMV disease and controls, and compared using the log-rank test. The impact of E-CMV, L-CMV-3M, and L-CMV-6M on the probability of graft rejection, graft failure, and all-cause mortality over 12 months after the index date adjusting for baseline comorbidities (diabetes and hypertension) was estimated using the multivariate logistic regression 
| Role of the funding source
The study sponsor (Astellas Pharma Global Development) contributed to the design of the study and provided funding for data collection, data analysis, and editorial support.
| RESULTS
A total of 20 473 patients who underwent a SOT in French hospitals between 2007 and 2011 were identified. The most common SOT performed was kidney transplantation (64.4%) ( T A B L E 1 Listing of cytomegalovirus (CMV) disease and graft rejection or failure ICD-10 codes
T A B L E 2 Demographic and clinical baseline characteristics
All SOT recipients
With CMV (n=1299)
Without CMV (n=2598) Chi-square test. SOT, solid organ transplantation; CMV, cytomegalovirus; E-CMV, CMV within 3 months post SOT; L-CMV-3M, CMV beyond 3 months post SOT; L-CMV-6M, CMV beyond 6 months post SOT; SD, standard deviation; MU, medical unit.
| Incidence of CMV disease
A diagnosis of CMV disease, within 24 months of transplantation, was recorded in 2430 recipients (11.9%) (Figure 1 ), of whom 295 (12.1%) developed CMV disease during the initial hospital stay. The incidence of CMV disease after SOT was 12.2% in kidney, 10.5% in liver, 8.7% in heart, 19.4% in lung, 2.6% in pancreas, 13.0% in intestine, and 10.8% in double organ transplants. Following SOT, E-CMV, L-CMV-3M, and L-CMV-6M were diagnosed in 1302 (6.4%), 1128 (5.5%), and 678 (3.3%) SOT recipients, respectively. Of these, 1299 (99.8%), 1114 (98.8%), and 666 (98.2%), respectively, could be matched with two controls and were included in the analyses ( Figure 1 ; Table 2 ).
3.2 | Impact of CMV disease on graft rejection, graft failure, and mortality
| E-CMV
Over the 24 months following the index date, graft rejection-free survival was significantly lower for recipients with E-CMV than for controls (P=.0001; Figure 2 ).
Among patients who were followed for at least 12 months, logistic regression analysis showed that E-CMV was associated with a signifi- Recipients with E-CMV who underwent kidney or other types of transplantation (heart, pancreas, double, and intestine) had significantly higher incidences of graft rejection than controls (Table 3 ).
In contrast, little difference in the incidence of graft failure between recipients with E-CMV and controls was observed for any transplanted organ type ( Figure 2 and Table 3 ). Logistic regression analysis indicated that E-CMV was not associated with an increased risk of graft failure (OR=1.18, 95% CI 0.92-1.50; P=.1906) ( Table 4 ).
In contrast, mortality, assessed through overall survival, was significantly higher in recipients with E-CMV than in controls across all transplanted organ types, except for kidney (OR=2.85, 95% CI 2.00-4.06;
P<.0001) (Figure 2 and Tables 3 and 4) .
| L-CMV-3M and L-CMV-6M
Graft rejection-free survival, graft failure-free survival, and overall survival were significantly lower among recipients with L-CMV-3M
or L-CMV-6M than controls (Figure 2 ). Recipients with L-CMV-3M F I G U R E 1 Solid organ transplant (SOT) recipient inclusion in the study. CMV, cytomegalovirus; E-CMV, early-onset CMV; L-CMV, late onset CMV; 3M, 3 months; 6M, 6 months and L-CMV-6M were more likely than controls to experience graft rejection and graft failure over 12 months following the index date (Table 3) . Logistic regression analysis confirmed an increased risk of graft rejection in recipients with L-CMV-3M (OR=1.50, 95% CI 1.13-2.00; P=.0053) and also with L-CMV-6M (OR=1.61, 95% CI 1.02-2.54; P=.0412) ( Table 4) . Compared with controls, the incidence of graft rejection was significantly higher only in recipients of kidney transplants with L-CMV-3M and L-CMV-6M (Table 3 ). In addition, both L-CMV-3M and L-CMV-6M were significantly associated with higher rates/risk of graft failure for all transplanted organs, except for lung recipients with L-CMV-3M (Tables 3 and 4) .
The risk of all-cause mortality increased more than fourfold over P=.0001) ( Table 4 ). Finally, mortality was significantly higher in recipients with L-CMV-3M and L-CMV-6M than in controls for all transplanted organs, except lung and other transplants in recipients with L-CMV-6M (Table 3 ).
| Impact of CMV disease on healthcare resource use
Over 12 months after the index date, the mean cumulative number of inpatient days, the mean number of hospital readmissions, and the mean total hospitalization costs were significantly higher in recipients with CMV disease, compared with controls (Table 3) .
For recipients with L-CMV-3M or L-CMV-6M, the mean number of inpatient days and hospital readmissions were two-to threefold higher than for controls, irrespective of the transplanted organ received.
Regression analyses showed that recipients with CMV disease used significantly more healthcare resources over the 12 months post CMV disease diagnosis than controls (Table 5 ). For instance, hospitalization costs increased by 39% (95% CI 26-54), 73% (95% CI 48-102), and 90% (95% CI 51-139), in recipients with E-CMV, L-CMV-3M, and L-CMV-6M, respectively (Table 5) .
Furthermore, additional analyses using generalized linear models confirmed that total inpatient days, number of hospital readmissions, and hospitalization costs were significantly increased in patients with E-CMV, L-CMV-3M, and L-CMV-6M (all P<.01), compared with controls ( Table 5 ).
| DISCUSSION
This retrospective analysis of data from the PMSI database for Unsurprisingly, E-CMV and/or L-CMV disease was significantly associated with longer hospital stays, an increased likelihood of hospital readmission, and increased healthcare costs.
The current study showed that, within 2 years following an SOT, around 1 in 10 patients will likely develop CMV disease, an incidence that is comparable to that reported in previous large studies (6%-19%, n=407-1427), [3] [4] [5] [6] 26, 27 although smaller or single-center studies have reported even higher incidences of CMV disease (29%-32%, n=31-67). 7-9 However, it should be noted that, given the nature of the PMSI database, the objective of this analysis was not to estimate the incidence of CMV disease, but to describe its impact on patients'
clinical and economic outcomes after SOT. Different factors can influence the incidence of CMV disease in SOT recipients, including the type of organ transplant, the presence of associated risk factors, and the duration of CMV prophylaxis. 3,4,6,28 Therefore, meaningful . 0001 13 Comparing recipients with and without CMV. Unless specified, the chi-square test was used for categorical variables and Student t test for continuous variables.
2
Fisher's exact test.
3
Heart, pancreas, double organ, and intestine. 4 Deaths occurring in hospital. (methods used and sensitivity of methods), sampling frequency, and time of screening for infection. 29 While controlling for all these factors was not possible, owing to the retrospective nature of our study, the incidence of CMV disease in our patient population (11.86%) was generally in the same range as that reported in other observational studies. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] In our population, 11% of CMV disease cases occurred in kidney recipients, whereas the incidence in other studies ranged from 6.2% to 38.4%. 6, 30 Similarly, in a retrospective study of heart transplant recipients, the 12-month incidence of CMV disease was 11.7%
31 compared with 8.8% in the current analysis; in liver transplant recipients, CMV disease developed in 5.5%-7.4% of recipients in previous studies, 12,32 compared with 6% in our population. Among lung transplant recipients, the incidence of CMV disease was 16% in our population, compared with 14.9%-32.0% in other studies. 8, 33 A unique feature of our study is that it focuses on outcomes after CMV infection. Previous studies have shown that CMV disease is associated with substantial increases in the risk of graft rejection and mortality, 4, 6, 8, 15, 23, 29 but it is then unclear whether graft rejection occurred before or after CMV disease, and whether a causal relationship exists between the two. While rejection can lead to an increase in the risk of CMV disease because of the use of more intensive immunosuppression, our study suggests that an increase in risk of rejection is a direct consequence of CMV disease. In general, estimates of the graft rejection and mortality risks in our study are consistent with other studies. We also found L-CMV disease to be associated with an increased risk of mortality and graft failure in SOT recipients. These results are noteworthy because previous studies examining the impact of CMV disease on graft failure did not allow the impact of E-CMV and L-CMV diseases to be distinguished. The key strengths of this study are that (i) the data were derived from a large national database (capturing data for all patients undergoing any type of SOT in France), and (ii) data were then stratified by time of CMV disease onset (early or two late stages), which provided a more detailed insight into the impact of CMV disease on clinical and economic outcomes. Nonetheless, several limitations of our study should be noted. The major limitation is that ICD-10 codes were the only way of identifying CMV disease retrospectively. However, the definition of CMV disease in SOT requires a constellation of symptoms (for CMV syndrome) or biopsy (for end-organ disease). While there is no guarantee that the ICD-10 codes reflect the correct diagnosis, this is the best approach possible in a retrospective study.
Using ICD-10 codes only to identify CMV disease would be a major limitation for the accurate estimation of CMV incidence and that is why we excluded this from our objectives. This fact is also a limitation for our objective of comparing outcomes of patients with or without a CMV disease diagnosis, but at least all patient data were consistently analyzed using the same diagnostic criteria. Other limitations include that no information was available on whether active CMV infection (but not disease) developed; therefore, it was not possible to examine the epidemiological and resource burden associated with reactivated CMV infection. In addition, the database did not record the serological status of the donor or recipient in the SOT; therefore, issues regarding serological status could not be explored, for example, in relation to L-CMV disease, which usually occurs after the cessation of prophylaxis, particularly in the D+/R− population. However, the role of CMV serology is not widely recommended for diagnosis after transplantation. 18 Therefore, the lack of serological data is not so relevant, as once CMV disease occurs, its clinical manifestations do not vary according to serological profile. Another limitation is that no information was available on antiviral treatment use, whether prophylactic or preemptive, or immunosuppression, both of which affect graft and patient outcomes. Information on deaths occurring outside the hospital and the exact date of diagnosis and procedures used was also unavailable in the PMSI database. Furthermore, it was not possible to account for the intensity of immunosuppressive therapy, owing to lack of data, which is a potentially important confounding factor. Lastly, as the PMSI database only includes data from hospitalized patients, CMV cases who are diagnosed and managed on an outpatient basis are not captured. Therefore, a bias toward more severe cases of CMV disease (i.e., those admitted to hospital) cannot be excluded.
In conclusion, this study demonstrates the value of using realworld data to evaluate the impact of CMV in SOT recipients. Our analysis contributes to the available evidence indicating that CMV disease remains a significant management challenge as it is associated with considerable burden, causing substantial increases in graft rejection, graft failure, mortality, and costs following SOT. These data reinforce the need for new strategies to prevent and manage CMV disease, in order to improve clinical and economic outcomes in SOT recipients.
